Marketing Architects Partners with Jounce Media for Greater Transparency in CTV Buying
Jounce Media Designates Yahoo Backstage as the Open Web's Largest MFA-Free Supply Source
Jounce (JNCE) Up 21% on Accepting Concentra's Buyout Offer
Penny Stocks To Buy Now: 7 To Watch Before Next Week
Jounce (JNCE) Up 41% on Buyout Offer From Concentra Biosciences
5 Top Penny Stocks To Buy In March According To Insiders
Navigating Volatile Penny Stocks: Essential Tips for Investors
Tang Capital Partners Now Owns 10.2% of Jounce Therapeutics
Why Is Jounce Therapeutics (JNCE) Stock Up 37% Today?
Maximizing Returns With Penny Stocks: Day Trading
Why Is Jounce Therapeutics (JNCE) Stock Up 14% Today?
Jounce: Gilead's GS-1811 Buyout Allows A Further Bounce
How to Read Penny Stocks News and Use it to Profit
Why Is Jounce Therapeutics (JNCE) Stock Up 70% Today?
Gilead buys out rights to cancer therapy from Jounce for $67 mln
Jounce stock bounces more than 70% after Gilead acquires immunotherapy drug
Gilead to Acquire All Remaining Rights to Potential First-in-Class Immunotherapy GS-1811 From Jounce Therapeutics
Jounce Therapeutics to Present Multiple Posters at the Society for Immunotherapy of Cancer's (SITC) 37th Annual Meeting and the European Society of Medical Oncology Immuno-Oncology (ESMO-IO) Annual Congress
Jounce Therapeutics to Participate in the Upcoming Investor Conferences
Jounce (JNCE) SELECT Study Fails to Meet Goal, Stock Down
Jounce Therapeutics, Inc. (JNCE) CEO Richard Murray on Q2 2022 Results - Earnings Call Transcript
Jounce Therapeutics to Present at Upcoming Investor Conferences
Jounce Therapeutics, Inc. (JNCE) CEO Richard Murray on Q1 2022 Results - Earnings Call Transcript
Jounce Therapeutics to Announce First Quarter 2022 Financial Results and Host Conference Call on Thursday, May 5, 2022
Jounce Therapeutics, Inc. (JNCE) CEO Richard Murray On Q4 2021 Results - Earnings Call Transcript
Jounce Therapeutics, Inc. (JNCE) Reports Q4 Loss, Lags Revenue Estimates
Jounce Therapeutics to Announce Fourth Quarter and Full Year 2021 Financial Results and Host Conference Call on Wednesday, March 2, 2022
Jounce Therapeutics: A Favorable Risk-Reward Ahead Of Critical 2022 Catalysts
Jounce Therapeutics to Present at Upcoming Investor Conferences in November
Jounce Therapeutics, Inc's. (JNCE) CEO Richard Murray on Q3 2021 Results - Earnings Call Transcript
Jounce Therapeutics to Report Third Quarter 2021 Financial Results and Host Conference Call on Thursday, November 4, 2021
Jounce Therapeutics Progresses INNATE Study of JTX-8064 (LILRB2/ILT4 Inhibitor) Monotherapy and Pimivalimab (PD-1 Inhibitor) Combination Therapy in Patients with Advanced Solid Tumors
Jounce Therapeutics Appoints Jigar Raythatha to its Board of Directors
Jounce Therapeutics, Inc. (JNCE) CEO Rich Murray on Q2 2021 Results - Earnings Call Transcript
Jounce Therapeutics Reports Second Quarter 2021 Financial Results
Jounce Therapeutics to Announce Second Quarter 2021 Financial Results and Host a Conference Call on Thursday, August 5, 2021
Jounce Therapeutics: An Under The Radar And Undervalued Biotech
Jounce Therapeutics to Participate in William Blair's Biotech Focus Conference
Why Jounce Therapeutics Bounced Higher Today
Stop Checking Your Portfolio: How to Invest for the Long Term During a Market Crash
Jounce Therapeutics, Inc. (JNCE) CEO Rich Murray on Q1 2021 Results - Earnings Call Transcript
Jounce Therapeutics, Inc. (JNCE) Reports Q1 Loss, Misses Revenue Estimates
Jounce Therapeutics Reports First Quarter 2021 Financial Results
Jounce Therapeutics to Present Trial in Progress Posters on the Phase 1 INNATE and the Phase 2 SELECT Clinical Trials at the 2021 American Society of Clinical Oncology (ASCO) Virtual Annual Meeting
Jounce Therapeutics Presents Preclinical Data from JTX-8064/LILRB2 Program at the 2021 American Association for Cancer Research (AACR) Virtual Annual Meeting
Conoco, Dow, Pure Storage, Signet Jewelers and More of Monday Afternoon's Analyst Calls
Jounce Therapeutics Announces Closing of Public Offering and Full Exercise of Over-Allotment Option
Jounce Therapeutics to Present Preclinical Data from JTX-8064 Program at the 2021 American Association for Cancer Research Virtual (AACR) Annual Meeting
Jounce Therapeutics Announces Pricing of $56.25 Million Public Offering of Common Stock
Jounce Therapeutics Announces Proposed Offering of Common Stock